{"organizations": [], "uuid": "f8b81e133de7a18d9a107e9ba4eec1ef75462563", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-announces-firs/brief-axsome-therapeutics-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-axs-05-in-smoking-cessation-idUSASC09WR7", "country": "US", "domain_rank": 408, "title": "BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T14:50:00.000+03:00", "replies_count": 0, "uuid": "f8b81e133de7a18d9a107e9ba4eec1ef75462563"}, "author": "", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-announces-firs/brief-axsome-therapeutics-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-axs-05-in-smoking-cessation-idUSASC09WR7", "ord_in_thread": 0, "title": "BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "smoking cessation reuters staff", "sentiment": "none"}, {"name": "axsome therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 11:50 AM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation Reuters Staff 1 Min Read \nApril 23 (Reuters) - Axsome Therapeutics Inc: \n* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-23T14:50:00.000+03:00", "crawled": "2018-04-23T15:04:50.016+03:00", "highlightTitle": ""}